DNAG: AI 评分 61/100 — AI 分析 (4月 2026)

DNAPrint Genomics, Inc. focuses on developing and marketing genetic testing products and services for ancestry, forensics, and pharmaceutical applications. The company offers specialized DNA assays and genotyping systems, serving diverse clients across forensic science, genealogical research, consumer products, and pharmaceutical development.

Key Facts: AI Score: 61/100 Sector: Healthcare

公司概况

概要：

DNAPrint Genomics, Inc. specializes in genetic testing products and services, offering ancestry analysis, forensic DNA tools, and genotyping systems. With a focus on serving forensic science, genealogical research, and pharmaceutical development clients, the company operates in the competitive biotechnology sector, marked by rapid innovation and evolving regulatory landscapes.

DNAG是做什么的？

DNAPrint Genomics, Inc., originally incorporated as Lexington Energy, Inc. in 1983, is a biotechnology company based in Sarasota, Florida, with a subsidiary in Leverkusen, Germany. The company develops and markets genetic testing products and services, catering to a diverse clientele across forensic science, genealogical research, consumer products, and pharmaceutical development. Its product portfolio includes AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; and EuropeanDNA, which reports a customer's proportional basic continental European ancestry. DNAPrint Genomics also offers DNAWitness, a tool used to determine genetic heritage from DNA samples obtained from crime scenes, and RETINOME, which provides a physical portrait of a person of interest based on a DNA sample. Additionally, RETINOME allows for inferring eye color from DNA. The company's GenomeLab SNPstream Genotyping System provides genotyping rates, utilizing a multiplexing format to generate data with minimal reagents. DNAPrint Genomics's focus on specialized genetic testing solutions positions it within a niche segment of the broader biotechnology market, emphasizing innovation and application across multiple sectors.

DNAG的投资论点是什么？

DNAPrint Genomics, Inc. operates in the niche market of genetic testing with products like AncestryByDNA and DNAWitness. The company's gross margin of 31.0% indicates potential for profitability if sales increase. However, the negative P/E ratio and a profit margin of -507.5% highlight significant financial challenges. Growth catalysts include expanding applications of RETINOME in forensics and increased adoption of GenomeLab SNPstream Genotyping System. Key risks involve the company's ability to achieve profitability and manage its operational costs. The high beta of 1.53 suggests the stock is more volatile than the market, adding a layer of risk for investors. Success hinges on effective commercialization and strategic partnerships.

DNAG在哪个行业运营？

DNAPrint Genomics, Inc. operates within the biotechnology industry, a sector characterized by rapid innovation, intense competition, and stringent regulatory oversight. The genetic testing market is experiencing growth, driven by advancements in technology and increasing demand for personalized medicine and ancestry services. DNAPrint Genomics competes with companies offering similar genetic testing services, including ancestry analysis and forensic DNA tools. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and establish strategic partnerships within the evolving landscape.

Biotechnology

Healthcare

DNAG有哪些增长机遇？

Expansion of RETINOME Applications in Forensics: DNAPrint Genomics can expand the application of its RETINOME technology in forensic science. The market for forensic DNA analysis is projected to reach $6.1 billion by 2028, growing at a CAGR of 11.2% from 2021. By enhancing the accuracy and capabilities of RETINOME, DNAPrint Genomics can capture a larger share of this market, providing law enforcement agencies with advanced tools for identifying suspects and solving crimes. This expansion requires strategic partnerships with forensic laboratories and continuous innovation in DNA phenotyping technologies.
Increased Adoption of GenomeLab SNPstream Genotyping System: The GenomeLab SNPstream Genotyping System offers high genotyping rates and efficient data generation, positioning it as a valuable tool for pharmaceutical development and research. The global genotyping market is expected to reach $12.5 billion by 2027. DNAPrint Genomics can drive adoption by targeting research institutions, pharmaceutical companies, and diagnostic labs. Demonstrating the system's cost-effectiveness and superior performance through case studies and collaborations will be crucial for market penetration.
Strategic Partnerships in Pharmaceutical Development: DNAPrint Genomics can leverage its expertise in genetic testing to form strategic partnerships with pharmaceutical companies. The pharmaceutical industry increasingly relies on genetic data to develop personalized medicine and targeted therapies. By offering customized genotyping services and ancestry analysis, DNAPrint Genomics can support drug discovery and clinical trials. These partnerships can provide a stable revenue stream and enhance the company's reputation in the pharmaceutical sector. The personalized medicine market is projected to reach $2.4 trillion by 2030.
Direct-to-Consumer Genetic Testing Expansion: DNAPrint Genomics can expand its direct-to-consumer (DTC) genetic testing services, focusing on ancestry analysis and personalized health insights. The DTC genetic testing market is growing, driven by increasing consumer interest in understanding their genetic heritage and health predispositions. By offering user-friendly testing kits and comprehensive reports, DNAPrint Genomics can attract a broader customer base. Marketing efforts should emphasize the accuracy and reliability of the company's testing methods, differentiating it from competitors in the crowded DTC market. The global DTC genetic testing market is expected to reach $6.2 billion by 2027.
Geographic Expansion into Emerging Markets: DNAPrint Genomics can pursue geographic expansion into emerging markets, where demand for genetic testing services is growing. Countries in Asia-Pacific and Latin America are experiencing increased investment in healthcare infrastructure and research. By establishing partnerships with local distributors and laboratories, DNAPrint Genomics can access these markets and offer its genetic testing products and services to a new customer base. Adapting its products to meet the specific needs and regulatory requirements of each market will be essential for successful expansion.

Gross Margin of 31.0% indicates potential for profitability with increased sales volume.
Profit Margin of -507.5% reflects significant operational losses and the need for improved cost management.
Beta of 1.53 suggests higher volatility compared to the overall market, indicating a riskier investment.
Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
The company serves diverse sectors including forensic science, genealogical research, consumer products, and pharmaceutical development, providing multiple revenue streams.

DNAG提供哪些产品和服务？

Develops and markets genetic testing products and services.
Offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry.
Provides EurasianDNA, which measures European sub-ancestry.
Offers EuropeanDNA, which reports proportional basic continental European ancestry.
Provides DNAWitness to determine genetic heritage from crime scene DNA samples.
Offers RETINOME, which provides a physical portrait based on DNA samples.
Offers RETINOME, which allows inferring eye color from DNA.
Provides GenomeLab SNPstream Genotyping System for genotyping.

DNAG如何赚钱？

Sales of genetic testing kits and services to consumers for ancestry analysis.
Providing forensic DNA analysis tools and services to law enforcement agencies.
Offering genotyping services and systems to pharmaceutical companies and research institutions.
Generating revenue through strategic partnerships and collaborations in the healthcare sector.

Individuals interested in ancestry and genealogy research.
Law enforcement agencies and forensic laboratories.
Pharmaceutical companies involved in drug discovery and clinical trials.
Research institutions conducting genetic studies.
Consumer product companies utilizing genetic data for product development.

Proprietary genetic testing technologies and assays.
Expertise in forensic DNA analysis and phenotyping.
Established relationships with forensic science and research institutions.
Diverse product portfolio catering to multiple market segments.

什么因素可能推动DNAG股价上涨？

Upcoming: Potential partnerships with pharmaceutical companies for personalized medicine initiatives.
Ongoing: Continued development and refinement of RETINOME technology for forensic applications.
Ongoing: Expansion of direct-to-consumer genetic testing services.
Upcoming: Potential for increased adoption of GenomeLab SNPstream Genotyping System in research institutions.

DNAG的主要风险是什么？

Ongoing: Negative profit margin and financial losses impacting long-term sustainability.
Potential: Intense competition in the biotechnology industry.
Potential: Stringent regulatory requirements and compliance costs.
Potential: Technological obsolescence of existing products.
Ongoing: Limited market capitalization and liquidity on the OTC market.

DNAG的核心优势是什么？

Specialized genetic testing products and services.
Expertise in ancestry analysis and forensic DNA tools.
Diverse customer base across multiple sectors.
Proprietary technologies like RETINOME and GenomeLab SNPstream.

DNAG的劣势是什么？

Negative profit margin and financial losses.
Limited market capitalization and liquidity.
Dependence on niche markets.
Unknown disclosure status on the OTC market.

DNAG有哪些机遇？

Expansion of RETINOME applications in forensics.
Increased adoption of GenomeLab SNPstream in pharmaceutical development.
Strategic partnerships with pharmaceutical companies.
Growth in direct-to-consumer genetic testing market.

DNAG面临哪些威胁？

Intense competition in the biotechnology industry.
Stringent regulatory requirements and compliance costs.
Potential for technological obsolescence.
Economic downturn affecting consumer spending and research budgets.

DNAG的竞争对手是谁？

Avantax, Inc. — Offers financial planning and wealth management solutions. — (AVXT)
BlueRock Diamonds PLC — Focuses on diamond mining and exploration. — (BRAXF)
IPAH — Unknown - No information available. — (IPAH)
Jinhui Mining Co., Ltd. — Engaged in mining operations. — (JNHMF)
Laredo Exploration, Inc. — Focuses on oil and gas exploration and production. — (LADX)

Key Metrics

MoonshotScore: 61/100

Company Profile

CEO: Jatin Patel
Headquarters: Sarasota, US
Employees: 24
Founded: 2001

AI Insight

AI analysis pending for DNAG

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does DNAPrint Genomics, Inc. do?

DNAPrint Genomics, Inc. develops and markets genetic testing products and services, focusing on ancestry analysis, forensic DNA tools, and genotyping systems. The company's offerings include AncestryByDNA, EurasianDNA, EuropeanDNA, DNAWitness, RETINOME, and the GenomeLab SNPstream Genotyping System. These products cater to a diverse clientele, including individuals interested in ancestry, law enforcement agencies, pharmaceutical companies, and research institutions. The company aims to provide innovative genetic solutions for various applications, leveraging its expertise in DNA analysis and phenotyping.

What do analysts say about DNAG stock?

As of 2026-03-18, formal analyst ratings for DNAG stock are unavailable, likely due to its listing on the OTC market and limited market capitalization. Given the company's negative profit margin and financial losses, investors should carefully evaluate the risks and potential rewards. Key valuation metrics such as P/E ratio are not meaningful due to negative earnings. Growth considerations include the company's ability to expand its market reach, secure strategic partnerships, and achieve profitability. Investors should conduct thorough due diligence and consider their risk tolerance before investing.

What are the main risks for DNAG?

The main risks for DNAPrint Genomics, Inc. include its negative profit margin and ongoing financial losses, which raise concerns about its long-term sustainability. The company faces intense competition in the biotechnology industry, requiring continuous innovation and differentiation. Stringent regulatory requirements and compliance costs can also impact profitability. Additionally, the risk of technological obsolescence and the limited market capitalization and liquidity associated with its OTC listing pose significant challenges for investors. The unknown disclosure status further compounds the risks, making it difficult to assess the company's financial health.